Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027
Go back to Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027| (NASDAQ: PPCB) | Delayed: 0.63 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.63 | 52 Week High | $ | |||
| Open | $0.63 | 52 Week Low | $ | |||
| Day High | $0.63 | P/E | N/A | |||
| Day Low | $0.63 | EPS | $ | |||
| Volume | 231 | |||||
